Gepotidacin CAS 1075236-89-3

Gepotidacin (CAS 1075236-89-3) User Guide

Table of Contents

• 1. Product Specifications & Comparative Analysis
• 2. Detailed Applications
• 3. Usage Scenarios
• 4. Implementation Case Studies
• 5. Client Success Stories
• 6. Request Consultation

1. Product Specifications & Comparative Analysis

2. Detailed Applications

Gepotidacin demonstrates exceptional efficacy in:

• Multidrug-resistant Neisseria gonorrhoeae infections
• Gram-positive bacterial infections (MIC90: ≤0.25 μg/mL)
• UTIs caused by ESBL-producing Enterobacteriaceae

3. Usage Scenarios

Typical implementation contexts include:

• Hospital formulary integration for MDR pathogen coverage
• Outpatient oral step-down therapy protocols
• Antimicrobial stewardship programs

4. Implementation Case Studies

Case 1: Regional Health System Adoption

Challenge: 42% ceftriaxone resistance in gonococcal isolates
Solution: Implemented gepotidacin-based empirical therapy
Outcome: 97% clinical cure rate at test-of-cure visit

Case 2: Pharmaceutical Development

Challenge: Need for novel Gram-positive coverage
Solution: Incorporated gepotidacin in combination therapy R&D
Outcome: Synergy demonstrated with β-lactams (FICI ≤0.5)

5. Client Success Stories

Client 1: European Research Hospital

• Patient Population: 550+ MDR infection cases annually
• Implementation: Gepotidacin susceptibility testing protocol
• Results: 68% reduction in empirical carbapenem use

Client 2: North American Pharma Company

• Application: Novel combination therapy development
• Technical Support: Provided stability data (-20°C to 25°C)
• Regulatory Outcome: Successful Phase IIb trial completion

6. Request Consultation

Contact our antimicrobial specialists:

Email: info@vivalr.com
Phone: (86) 15866781826

Technical Support Includes:

• Stability profile analysis
• Comparative MIC data sets
• Regulatory compliance guidance